Preview

Rational Pharmacotherapy in Cardiology

Advanced search

PATHOGENETIC MECHANISMS AND TREATMENT PRINCIPLES OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION

https://doi.org/10.20996/1819-6446-2011-7-2-199-203

Full Text:

Abstract

Data about chronic thromboembolic pulmonary hypertension (CTPH) prevalence is presented. The main CTPH clinical manifestations are described. The possible reasons and pathogenetic mechanisms of CTPH development are discussed. Features of unfavorable disease prognosis are also presented. Indications, results, limitations for CTPH surgical treatment are shown. Data of the currently completed clinical studies on bosentan, prostacyclin analogues and phosphodiesterase-5 inhibitors usage in CTPH are presented.

About the Authors

N. A. Shostak
Russian State Medical University
Russian Federation


A. A. Klimenko
Russian State Medical University
Russian Federation


N. A. Demidova
Russian State Medical University
Russian Federation


I. V. Novikov
Russian State Medical University
Russian Federation


References

1. Magidson O., Jabson G. Trombosis of the main pulmonary arteries. Br Heart J 1955; 17: 207-218

2. Gibbon JH. Jr., Hopkinson M., Churchill E.D. Changes in the circulation produced by gradual occlusion of the pulmonary artery. J Clin Invest 1932; 11(3):543–553

3. Dentali F., Donadini M., Gianni M. et al. Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism. Thromb Res 2009; 124(3):256-258

4. Savel'ev V.S., editor. Phlebology. Guide for Physicians. M.: Meditsina; 2001. Russian (Са-вельев В.С., редактор. Флебология. Руководство для врачей. М.: Медицина; 2001)

5. Fedullo P.F., Auger W.R., Channick R.N. et al. Chronic thromboembolic pulmonary hypertension. Clin Chest Med 1995;16:353–374

6. Riedel M., Stanek V., Widimsky J., Prerovsky I. Longterm Follow-up of Patients with Pulmonary Thromboembolism. Chest 1982;81;151-158

7. Grifoni S., Olivotto I., Cecchini P. et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation 2000;101(24):2817-22

8. Tunariu N., Gibbs SJ., Win Z. et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 2007;48:680-684

9. Galiè N., Hoeper M.M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-2537

10. Torbicki A. Pulmonary thromboembolic disease. Clinical management of acute and chronic disease. Rev Esp Cardiol 2010;63(7):832-849

11. Dartevelle P., Fadel E., Mussot S. et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2004; 23:637-648

12. Wolf M., Boyer-Neumann C., Parent F. et al. Thrombotic risk factors in pulmonary hypertension. Eur Respir J 2000;15:395–399

13. Arnoni R.T., Jatene F.B., Bernardo W.M. et al. Medial hypertrophy in patients with pulmonary embolism: anatomopathological study. Arq Bras Cardiol 2007;88(6):660-666

14. Roytberg G.E., Strutynskiy A.V. Internal medicine. Circulatory system. M.: Binom; 2003. Russian (Ройтберг Г.Е., Струтынский А.В. Внутренние болезни. Сердечно-сосудистая система. М.: Бином; 2003).

15. Galie N., Manes A., Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004; 61: 227-237

16. Bauer M., Wilkens H., Langer F. et al. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 2002; 105: 1034-1036

17. Humbert M., Morrell N.W., Archer S.L. et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:13–24

18. Reesink H.J., Meijer R.C., Lutter R. et al. Hemodynamic and Clinical Correlates of Endothelin-1 in Chronic Thromboembolic Pulmonary Hypertension. Circ J 2006; 70: 1058-1063

19. Dentali F., Donadini M., Gianni M. Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism. Intern Emerg Med. 2009; 4(2): 123-128

20. Mukoyama M., Nakao K., Hosoda K. et al. Brain natriuretic peptide as a novel cardiac hormone in humans: Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991;87:1402 -1412

21. Fijalkowska A., Kurzyna M., Torbicki A. et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006; 129(5):1313-1321

22. Donadini M., Dentali F., Ageno W. Brain natriuretic peptide and preclinical chronic thromboembolic pulmonary hypertension. Intern Emerg Med 2009;4:441-442

23. Reesink H.J., Tulevski I.I., Marcus J.T. et al. Brain natriuretic peptide as noninvasive marker of the severity of right ventricular dysfunction in chronic thromboembolic pulmonary hypertension. Ann Thorac Surg 2007;84(2):537-43

24. Von Haehling S., von Bardeleben R.S., Kramm T. et al. Inflammation in right ventricular dysfunction due to thromboembolic pulmonary hypertension. Int J Cardiol 2010;144(2):206-11.

25. Pelsers M.M., Hermens W.T., Glatz J.F. Fatty acid-binding proteins as plasma markers of tissue injury. Clinica Chimica Acta 2005;352:15-35

26. Haltern G., Peiniger S., Bufe A. et al. Comparison of usefulness of heart-type fatty acid binding protein versus cardiac troponin T for diagnosis of acute myocardial infarction. Am J Car-diol 2010;105(1):1-9

27. Puls M., Dellas C., Lankeit M. et al. Heart-type fatty acidbinding protein permits early risk stratification of pulmonary embolism. Eur Heart J 2007;28:224-229

28. Orfanos S.E., Zakynthinos S. Heart biomarkers as prognostic tools for chronic thromboembolic pulmonary hypertension: a step forward by the fatty acid-binding protein. Eur Respir J 2008;31:915-917

29. Lankeit M., Dellas C., Panzenbock A. et al. Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension. Eur Respir J 2008;31:1024-1029

30. Hollister L., Cull V. The syndrome of chronic thrombosis of the major pulmonary arteries. American Journal of Medicine 1956;21:312—320

31. Savel'ev B.C., Yablokov E.G., Kirienko A.I. Massive pulmonary thromboembolism. M: Med-itsina; 1990. Russian (Савельев B.C., Яблоков Е.Г., Кириенко А.И. Массивная тром-боэмболия легочной артерии. М: Медицина; 1990)

32. Keogh A., Mayer E., Benza R. et al. Interventional and surgical modalities of treatment in pulmonary hypertension. J Am Coll Cardiol 2009;54:S67–S77

33. Wittine L.M., Auger W.R. Chronic Thromboembolic Pulmonary Hypertension. Curr Treat Options Cardiovasc Med 2010;12(2):131–141

34. Condliffe R., Kiely D.G., Gibbs S.R. et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Resp Crit Care Med 2008;177:1122–1127

35. Corsico A.G., D’Armini A.M., Cerveri I. et al. Long-term outcome after pulmonary en-darterectomy. Am J Respir Crit Care Med 2008;178:419–424

36. Ono F., Nagaya N., Okumura H. et al. Effect of orally active prostacyclin analogue on survival in patients with chronic thromboembolic pulmonary hypertension without major vessel obstruction. Chest 2003; 123(5):1583—1588

37. Lapina T.V., Vishnevskiĭ A.A. Methods of treatment of chronic thromboembolic pulmonary hypertension. Khirurgiya. Zhurnal im. N.I. Pirogova 2007; 4:58—61. Russian (Лапина Т.В., Вишневский А.А. Методы лечения хронической тромбоэмболической легочной гипертензии. Хирургия. Журнал им. Н.И. Пирогова 2007; 4:58—61)

38. Jamieson S., Kapelanski D., Sakakibara N. et al. Pulmonary endarterectomy: experience and lessons learned in 1, 500 cases. Ann Thorac Surg 2003;76:1457–1464

39. Bresser P., Pepke-Zaba J., Jais X. et al. Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm. Proc Am Thorac Soc 2006;3:594–600

40. Galiè N., Palazzini M., Leci E., Manes A. Current Therapeutic Approaches to Pulmonary Arterial Hypertension Rev Esp Cardiol 2010;63(6):708-724

41. Bonderman D., Jakowitsch J., Adlbrecht C. et al. Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thromb Haemost 2005;93:512-516

42. Mayer E., Kramm T., Dahm M. et al. Surgical treatment of chronic thromboembolic pulmonary hypertension. Acta Chirurgica Austriaca 1999;31:308—331

43. Auger W.R., Fedullo P.F. Chronic thromboembolic pulmonary hypertension. Sem Resp Crit Care Med. 2009;30:471–483

44. Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J 2003;24:761-781

45. Reichenberger F., Voswinckel R., Enke B. et al. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Resp J 2007;30:922–927

46. Hughes R.J., Jais X., Bonderman D. et al. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Resp J 2006;28:138–143

47. Cabrol S., Souza R., Jais X. et al. Intravenous epoprostenol in inoperable chronic thromboembolic disease. J Heart Lung Transplant 2007;26:357–362

48. Reesink H.J., Surie S., Kloek J.J. et. аl. Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary. J Thorac Cardiovasc Surg 2010; 139(1):85-91

49. Jais X., D’Armini A., Jansa P. et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 2008;52:2127–2134

50. Wharton J., Strange J.W., Moller G.M. et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005; 172:105–113

51. Suntharalingam J., Treacy C., Doughty N. et al. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest 2008;134;229-236

52. Badesch D.B., Hill N.S., Burgess G. et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 2007;34:2417-2422

53. Jones D.A., Benjamin C.W., Linseman D.A. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle tell growth and mitogen-activated protein kinase signaling cascades. Mol Pharmacol 1995;48:890-896

54. Nagaya N., Sasaki N., Ando M. et al. Prostacyclin therapy before pulmonary thromboendarterec tomy in patients with chronic thromboembolic pulmonary hypertension. Chest 2003;123:338–343

55. Skoro-Sajer N., Bonderman D., Wiesbauer F. et al. Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension. J Thromb Haemost 2007;5:483–489

56. Krug S., Hammerschmidt S., Pankau H. et al. Acute improved hemodynamics following inhaled iloprost in chronic thromboembolic pulmonary hypertension. Respiration 2008;76:154–159

57. Kramm T., Eberle B., Krummenauer F. et al. Inhaled iloprost in patients with chronic thromboembolic pulmonary hypertension: effects before and after pulmonary thromboendarterectomy. Ann Thorac Surg 2003;76(3):711-718

58. Kerr K.M., Rubin L.J. Epoprostenol therapy as a bridge to pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Chest 2003;123:319–320


For citation:


Shostak N.A., Klimenko A.A., Demidova N.A., Novikov I.V. PATHOGENETIC MECHANISMS AND TREATMENT PRINCIPLES OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION. Rational Pharmacotherapy in Cardiology. 2011;7(2):199-203. (In Russ.) https://doi.org/10.20996/1819-6446-2011-7-2-199-203

Views: 343


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)